CytomX Therapeutics, Inc. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 30 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $663K | ↓-98.3% | — | — | — |
| 2025-09-30 | $6M | ↓-82.2% | $-14M | ↓-348.1% | -264.4% |
| 2025-06-30 | $19M | ↓-25.7% | $-154K | ↑+97.6% | -6.9% |
| 2025-03-31 | $51M | ↑+22.8% | $24M | ↑+70.6% | 44.4% |
| 2024-12-31 | $38M | ↑+43.2% | $19M | ↑+2155.2% | 46.4% |
| 2024-09-30 | $33M | ↑+26.7% | $6M | ↑+91.7% | 12.3% |
| 2024-06-30 | $25M | ↑+1.6% | $-7M | ↓-501.1% | -33.7% |
| 2024-03-31 | $41M | ↑+76.4% | $14M | ↑+516.5% | 28.1% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$663K
↓-98.3% -$37M YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
CTMX Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyCTMX Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics